KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Leases: 2020-2021

Historic Capital Leases for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Dec 2021 value amounting to $9.3 million.

  • Recursion Pharmaceuticals' Capital Leases rose 244.87% to $9.3 million in Q4 2021 from the same period last year, while for Dec 2021 it was $9.3 million, marking a year-over-year increase of 244.87%. This contributed to the annual value of $9.3 million for FY2021, which is 244.87% up from last year.
  • As of FY2021, Recursion Pharmaceuticals' Capital Leases stood at $9.3 million, which was up 244.87% from $2.7 million recorded in FY2020.
  • Over the past 5 years, Recursion Pharmaceuticals' Capital Leases peaked at $9.3 million during FY2021, and registered a low of $2.7 million during FY2020.
  • In the last 2 years, Recursion Pharmaceuticals' Capital Leases had a median value of $6.0 million in 2020 and averaged $6.0 million.
  • Data for Recursion Pharmaceuticals' Capital Leases shows a peak YoY soared of 244.87% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows Recursion Pharmaceuticals' Capital Leases stood at $2.7 million in 2020, then soared by 244.87% to $9.3 million in 2021.